Serum prostate-specific antigen profile following radiotherapy for prostate cancer: Implications for patterns of failure and definition of cure

Urology

Volumn 51, Issue 4, 1998, Pages 566-572

  Crook, J M ^a   Choan, E ^b   Perry, G A ^b   Robertson, S ^b   Esche, B A ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; STEROID; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REFERENCE VALUE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; TREATMENT FAILURE;

EID: 0031954662     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00650-X     Document Type: Article

References (26)

1. Bagshaw MA, Cox RS, and Hancock SL: Control of prostate cancer with radiotherapy: long-term results. J Urol 152(5 Pt 2): 1781-1785, 1994.
2. 0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys 30: 289-292, 1994.
3. Cox RS, Kaplan ID, and Bagshaw MA: Prostate-specific antigen kinetics after external beam irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 28: 23-31, 1994.
4. Kaplan ID, Cox RS, and Bagshaw MA: Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. J Urol 149: 519-522, 1993.
5. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, and Bostwick DG: A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 79: 337-344, 1997.
6. Zagars GK, Pollack A, and von Eschenbach AC: Prostate cancer and radiation therapy - the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 33: 23-35, 1995.
7. Zelefsky MJ, Leibel SA, Wallner KE, Whitmore WF Jr, and Fuks Z: Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J Clin Oncol 13: 459-463, 1995.
8. Zietman AL, Coen JJ, Shipley WU, Willett CG, and Efird JT: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen values as a predictor of treatment outcome. J Urol 151: 640-645, 1994.
9. Crook JM, Perry GA, Robertson S, and Esche BA: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 45: 624-631, 1995.
10. Hermanek P, and Sobin LH (Eds): International Union Against Cancer. TNM Classification of Malignant Tumours, 4th ed, 2nd rev. Berlin, Springer-Verlag, 1992.
11. Brawer MK, Nagle RB, Pitts W, Freiha F, and Gamble SL: Keratin immunoreactivity as an aid to diagnosis of persistent adenocarcinoma in irradiated human prostates. Cancer 63: 454-460, 1989.
12. Scardino PT: The prognostic significance of biopsies after radiotherapy for prostatic cancer. Semin Urol 1: 243-252, 1983.
13. Crook J, Robertson S, Collin G, Zaleski V, and Esche B: Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 26: 31-37, 1993.
14. Crook JM, Bahadur YA, Robertson SJ, Perry GA, and Esche BA: Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 79: 81-89, 1997.
15. Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, and Coia LR: Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys (in press).
16. Rosenzweig KE, Morgan WR, Lytton B, and Peschel RE: Prostate specific antigen following radiotherapy for local prostate cancer. J Urol 153: 1561-1564, 1995.
17. Willett CG, Zietman H, Shipley WU, and Coen JJ: The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol 151: 1579-1581, 1994.
18. Crook JM, Bahadur YA, Bociek RG, Perry GA, Robertson SJ, and Esche BA: Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer 79: 328-336, 1997.
19. Critz FA, Levinson AK, Williams WH, and Holladay DA: Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. J Clin Oncol 14: 2893-2900, 1996.
20. Geist RW: Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate. Urology 45: 1016-1021, 1995.
21. Zagars GK, and Pollack A: The fall and rise of prostate specific antigen. Kinetics of serum prostate specific antigen after radiation therapy for prostate cancer. Cancer 72: 832-842, 1993.
22. Ritter MA, Messing EM, Shanahan TG, Potts S, Chapell RJ, and Kinsella TJ: Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 10: 1208-1217, 1992.
23. Trapasso JG, deKernion JB, Smith RB, and Dorey F: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152(5 Pt 2): 1821-1825, 1994.
24. Stamey TA, Ferrari MK, and Schmid HP: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 150: 1856-1859, 1993.
25. D'Amico AV, and Hanks GE: Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72: 2638-2643, 1993.
26. Lee WR, Hanks GE, and Hanlon A: Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 15: 230-238, 1997.